• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·300497.SZ
Share

Jiangxi Fushine Pharmaceutical Co., Ltd. Stocks

CN¥ 19.69Last Updated 11.09.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

CN¥ 1.47B

CN¥ 19.69
Key Takeaways

Risk factor

High price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Jiangxi Fushine Pharmaceutical Co., Ltd. is engaged in the global research, development, production, and marketing of active pharmaceutical ingredients (APIs) and key chemical compounds for drug synthesis. Its product portfolio includes important antibiotics like penicillin and carbapenem, alongside a variety of other pharmaceutical offerings. The company also extends its expertise by providing contract research, development, and manufacturing services. Founded in 2002 and headquartered in Jingdezhen, China, the firm was initially named Jingdezhen Fuxiang Pharmaceutical Co., Ltd. before adopting its current designation in August 2012.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 300497.SZ is 26.0 and suggests 30.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.09.2026 17:37

Inflation in the U.S. in August came in slightly above expectations. What can we expect from the Fed now?

11.09.2026 17:24

"A Recipe for Volatility": Why BofA Sees Risks in Market Calm

11.09.2026 15:00

Uber's CEO Invested $10 Million in the Company's Shares, Which Had Fallen in Price

11.09.2026 13:30

An investor from "Shorting" advised buying wine amid the dollar's decline

11.09.2026 13:11

Diesel prices in the U.S. have exceeded $6 per gallon for the first time in history

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026